ImageneBio, Inc.
IMANasdaq
$5.38
↓ -1.3%Jul 17 close · end-of-day
Price
1Y↓ -65.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$60.3M
Enterprise Value
-$56.9M
P/E
—
P/S
—
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$49.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-40.5%
ROIC
-704.1%
Debt / Equity
—
Net Cash
$117.2M
Return 1Y
-64.4%
Company profile
Ikena Oncology, Inc. focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
- CEO
- Mark Manfredi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- Massachusetts
- Website
- ikenaoncology.com
Management & directors
- Yarema KristinChief Executive Officer
- Butler ErinPrincipal Accounting Officer
- Marango JotinChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
IMA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.95↓ -75.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.2M | $31.0M | $15.6M | $9.2M | $3.5M | $800,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$44.5M | -$34.1M | -$70.9M | -$75.4M | -$37.0M | -$48.5M |
| Net income | -$44.3M | -$34.1M | -$68.8M | -$68.2M | -$36.6M | -$45.3M |
| Diluted EPS | — | -$1.22 | -$1.90 | -$1.63 | -$22.10 | -$9.64 |
| Operating cash flow | -$37.8M | -$60.3M | -$74.1M | -$79.7M | -$21.3M | -$47.8M |
| Free cash flow | -$38.6M | -$62.0M | -$75.5M | -$80.2M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -484.2% | -110.2% | -454.0% | -823.3% | -1057.1% | -6056.4% |
| Net margin | -481.4% | -110.1% | -440.3% | -744.2% | -1044.8% | -5668.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.5M | — | $800,000.00 | — | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.8M | -$2.0M | -$915,000.00 | -$6.0M | -$8.8M | -$26.6M | -$7.1M | -$12.1M |
| Net income | -$6.3M | -$3.2M | -$4.8M | -$6.1M | -$7.6M | -$24.8M | -$6.9M | -$10.6M |
| Diluted EPS | -$0.28 | -$2.58 | -$18.91 | -$3.80 | -$0.06 | -$2.91 | -$2.87 | -$0.95 |
| Operating cash flow | -$12.5M | $13.0M | -$3.5M | -$7.2M | -$6.8M | -$26.6M | -$7.2M | -$14.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -58.2% | — | -749.4% | — | — | — | — |
| Net margin | — | -90.9% | — | -759.6% | — | — | — | — |
Company news
May 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-16 | Yarema Kristin· Chief Executive Officer | Award | 85,400 | $0.00 | $0.00 | filing |
| 2025-12-30 | Butler Erin· Principal Accounting Officer | Award | 22,500 | $0.00 | $0.00 | filing |
| 2025-12-24 | SLATTERY JOSEPH P | Buy | 16,000 | $5.99 | $95,840.00 | filing |
| 2025-07-28 | Marango Jotin· Chief Financial Officer | Tax withholding | 4,630 | $17.16 | $79,450.80 | filing |
| 2025-07-28 | Marango Jotin· Chief Financial Officer | Award | 15,776 | — | — | filing |
| 2025-07-25 | Stampacchia Otello | Buy | 267,556 | $29.90 | $8.0M | filing |
| 2025-07-25 | Bonita David P | Buy | 83,611 | $29.90 | $2.5M | filing |
| 2025-07-25 | ORBIMED ADVISORS LLC | Award | 83,611 | $2.49 | $208,191.39 | filing |
| 2025-07-25 | Butler Erin· Principal Accounting Officer | Award | 3,051 | — | — | filing |
| 2025-07-25 | Wang Stephen Hui | Award | 188,042 | — | — | filing |
| 2025-07-25 | Wang Stephen Hui | Award | 50,144 | — | — | filing |
| 2025-07-25 | Wang Stephen Hui | Award | 12,535 | — | — | filing |
| 2025-07-25 | Wang Jonathan Jian | Award | 143,832 | — | — | filing |
| 2025-07-25 | Wang Jonathan Jian | Award | 971,173 | — | — | filing |
| 2025-07-25 | Bonita David P | Option exercise | 379 | — | — | filing |
| 2025-07-25 | Stampacchia Otello | Option exercise | 379 | — | — | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.